Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676843 · ClinicalTrials.gov registry record · Phase 2
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02676843 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 7 participants.
The verdict
NCT02676843, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.
Interventions
- DRUG 18F-AV-1451
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02676843
The ClinicalTrials.gov registry entry for NCT02676843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-AV-1451 is the first listed.
NCT02676843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02676843 about?
NCT02676843 is a clinical study titled "Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations". The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed ...
What is the current status of trial NCT02676843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-04. Estimated completion is 2018-11-25.
What interventions are being tested in trial NCT02676843?
The interventions under investigation include: 18F-AV-1451 (DRUG).
Who is sponsoring clinical trial NCT02676843?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.